Posaconazole

Latin: Posaconazolum

J02AC04

White powder

Antifungal

Inhibition of the biosynthesis of ergosterol for fungi

170-172 ° C

Insoluble in water

Template: Infobox chemical / molecular formula search available

Posaconazole is an antifungal agent from the group of triazoles. It inhibits ergosterol biosynthesis and since October 2005 under the trade name Noxafil ® ( Essex Pharma) on the market. Posaconazole is currently seen as an antifungal medication which is to be in serious, or itraconazole or amphotericin B- resistant fungal infections, especially in immunocompromised patients, applied. It is also currently approved only for the treatment of adults. In other patients, or uncomplicated fungal infections the azoles itraconazole and fluconazole are still considered the first choice.

Pharmacology

Posaconazole inhibits 14α -demethylase, a fungal specific cytochrome P450 isoenzyme ( CYP51A1 ), which is responsible for the conversion of lanosterol to ergosterol. Ergosterolvorstufen be incorporated into the membrane and the permeability of cell components increases.